Evidence map›Paper›PMID 27371521›Full record

ReviewHeart failure clinics2016

Novel Biological Therapies Targeting Heart Failure: Myocardial Rejuvenation.

Amanda J Favreau-Lessard, Sergey Ryzhov, Douglas B Sawyer

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heart failure clinics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Effects of endogenous serum neuregulin-1β on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction.Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Amanda J Favreau-LessardCenter for Molecular Medicine, Maine Medical Center Research Institute, Maine Medical Center, 81 Research Drive, Scarborough, ME 04074, USA.
Sergey RyzhovCenter for Molecular Medicine, Maine Medical Center Research Institute, Maine Medical Center, 81 Research Drive, Scarborough, ME 04074, USA.
Douglas B SawyerCenter for Molecular Medicine, Maine Medical Center Research Institute, Maine Medical Center, 81 Research Drive, Scarborough, ME 04074, USA. Electronic address: DSawyer@mmc.org.
Maine Medical Center Research Institute · USMaine Medical Center · US

Funding

Optimizing Cardiovascular Stem Cells for Cardiac Repair and RegenerationU01HL100398 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HATZOPOULOS, ANTONIS · 2009 to 2015
$8.0M
NHLBI NIH HHS U01 HL100398
6 · The paper itself

Abstract

Recovery of ventricular function occurs in a subset of patients with advanced heart failure treated with medical and/or mechanical therapy. Finding strategies that induce ventricular recovery through induction of repair, regeneration, or "rejuvenation" is a long-sought goal of research programs. Cell-based strategies, use of recombinant growth and survival factors, and gene delivery are under investigation. In this brief article we highlight a few of the biological approaches in development to treat heart failure.

Indexed as

Biological TherapyGenetic TherapyHeart FailureHumansRejuvenationSignal TransductionStem Cell TransplantationTranslational Research, BiomedicalCell therapyGene therapyHeart failureRejuvenation

Identifiers

PMID27371521
PMCPMC5214584
OpenAlexW2461409397

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.